Tropicamide/phenylephrine

Last updated

Tropicamide/phenylephrine
Combination of
Tropicamide Anticholinergic
Phenylephrine Alpha-1 adrenergic receptor agonist
Clinical data
Trade names Mydcombi
Routes of
administration 		Topical, ophthalmic
ATC code
Legal status
Legal status

Tropicamide/phenylephrine, sold under the brand name Mydcombi is a fixed dose combination of tropicamide and phenylephrine used to dilate the eyes (mydriasis). [1] It contains, tropicamide, an anticholinergic, and phenylephrine, as the hydrochloride, an alpha-1 adrenergic receptor agonist. [1] It is sprayed into the eyes. [1]

Contents

It was approved for medical use in the United States in May 2023. [2] [3]

Medical uses

Tropicamide/phenylephrine is used for the short-term dilation of the pupils. [1]

References

  1. 1 2 3 4 5 "Highlights of prescribing information - MYDCOMBI (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5%, for topical ophthalmic use" (PDF). Archived from the original (PDF) on 9 May 2023.
  2. ↑ "Mydcombi: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 8 May 2023.
  3. ↑ "Eyenovia Announces FDA Approval of Mydcombi, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company's Proprietary Optejet Device Platform". Eyenovia. 8 May 2023. Retrieved 8 May 2023.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.